DISCLOSURE] Alteogen (196170) said on Dec. 22 that its biosimilar of Roche’s breast cancer antibody Herceptin has cleared phase 1 clinical trials in Canada.
Background: ALT-P1 (CJ-40002) is a long-acting recombinant growth hormone (GH) fused with NexP, which is a long-acting carrier developed by Alteogen Inc. NexP is a protein engineered recombinant alpha
Health Canada approved a phase I trial for Alteogen’s ALT02, a biosimilar version of trastuzumab
 1  2  3  4